PASSARO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 419
EU - Europa 108
AS - Asia 62
AF - Africa 4
OC - Oceania 1
SA - Sud America 1
Totale 595
Nazione #
US - Stati Uniti d'America 414
IT - Italia 55
SG - Singapore 23
SE - Svezia 22
IN - India 20
CN - Cina 18
FI - Finlandia 12
CA - Canada 5
DE - Germania 5
PL - Polonia 4
GB - Regno Unito 3
TG - Togo 3
IE - Irlanda 2
UA - Ucraina 2
AR - Argentina 1
BG - Bulgaria 1
IR - Iran 1
NZ - Nuova Zelanda 1
RS - Serbia 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 595
Città #
Fairfield 71
Cambridge 35
Seattle 35
Ashburn 32
Woodbridge 29
Chandler 28
Santa Clara 23
Houston 21
Singapore 17
Wilmington 17
Beijing 15
Princeton 13
Rome 11
Plano 9
San Paolo di Civitate 8
Ann Arbor 6
Cagliari 6
Lawrence 6
Helsinki 5
Dearborn 4
Millbury 4
New York 4
Toronto 4
Fremont 3
Lomé 3
Andover 2
Boston 2
Catania 2
Dublin 2
Munich 2
Ningbo 2
Redmond 2
San Diego 2
Somma Lombardo 2
Auckland 1
Bologna 1
Des Moines 1
Federal 1
Jacksonville 1
Lodz 1
Los Angeles 1
Milan 1
Montréal 1
Muizenberg 1
New Delhi 1
Norwalk 1
Polska 1
Pune 1
San Mateo 1
Santi Cosma E Damiano 1
Sassuolo 1
Simi Valley 1
Sofia 1
Southend 1
Tianjin 1
Washington 1
Totale 449
Nome #
Antiangiogenic agents are ineffective to increase complete response rate in MRCC:A meta-analysis 85
Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules 85
The Impact of Chemotherapy on the Lymphatic System in Thoracic Oncology 72
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 72
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research? 65
Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer 64
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? 59
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. 58
null 30
Valutazione prospettica di una signature circolante come fattore predittivo di risposta nel carcinoma polmonare non a piccole cellule (NSCLC) trattato con Nivolumab in seconda linea 17
Totale 607
Categoria #
all - tutte 1.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.666


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202090 0 0 0 0 0 16 16 13 14 20 7 4
2020/202134 4 4 1 2 2 3 0 5 7 2 4 0
2021/202284 1 6 13 0 9 4 0 11 4 10 11 15
2022/2023103 22 21 8 6 13 11 2 5 9 1 2 3
2023/202446 5 3 2 3 6 10 0 9 0 1 2 5
2024/202555 2 2 14 2 28 7 0 0 0 0 0 0
Totale 607